LoginRegister

    Alembic JV Aleor Derma gets 1 USFDA observation for Karakhadi facility

    Medical Dialogues BureauWritten by Medical Dialogues Bureau   |  
    Alembic JV Aleor Derma gets 1 USFDA observation for Karakhadi facility

    Aleor Derma's formulation manufacturing facility located at Karakhadi, Gujarat got one observation after the completion of USFDA inspection. The inspection was carried out from 15th September 2019 to 20th September 2019.


    New Delhi: Drugmaker Alembic Pharmaceuticals Ltd. (Alembic) recently informed the exchange that the United States Food and Drug Administration (USFDA) has completed inspection of its Joint Venture, Aleor Dermaceuticals Ltd.


    Aleor Derma's formulation manufacturing facility located at Karakhadi, Gujarat got one observation after the completion of USFDA inspection. The inspection was carried out from 15th September 2019 to 20th September 2019.


    Also Read: Alembic Pharma JV Aleor gets USFDA nod for Clobetasol Propionate ointment


    Aleor Derma is a 60:40 joint venture between Alembic and Orbicular Pharmaceutical Technologies Pvt Ltd.


    "Aleor Dermaceuticals (Aleor), a 60:40 Joint Venture between Alembic Pharmaceuticals (Alembic) and Orbicular Pharmaceutical Technologies (Orbicular), has completed United States Food and Drug Administration (USFDA) inspection at its formulation manufacturing facility located at Karakhadi, Gujarat, India; with one observation, " Alembic said in a filing.


    Alembic Pharmaceuticals Ltd. is headquartered in Vadodara city of Gujarat. The company is involved in manufacturing of pharmaceutical products, pharmaceutical substances and intermediates. It is also termed to be a market leader in macrolides segment of anti-infective drugs in India.


    Read Also: Alembic Pharma gets USFDA approval for Fenofibrate tablets to lower cholesterol

    +USFDA ObservationAlembicAlembic JvAlembic PharmaAleor dermaAleor DermaceuticalsGujaratHealthcarejoint ventureKarakhadi facilityOrbicular Pharmapharmapharma companypharma newspharma news indiaUnited States Food and Drug AdministrationUSFDAUSFDA inspection

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X